Merck to pause two late-stage studies testing Keytruda in myeloma

(Reuters) - Merck & Co said on Monday it paused enrolments in two late-stage studies testing its immunotherapy drug Keytruda used in combination with other therapies to treat multiple myeloma, a type of blood cancer.